Acylated Insulin Analogs
    4.
    发明授权
    Acylated Insulin Analogs 失效
    酰化胰岛素类似物

    公开(公告)号:US5922675A

    公开(公告)日:1999-07-13

    申请号:US979587

    申请日:1997-11-26

    CPC分类号: C07K14/62 A61K38/00

    摘要: The present invention relates to the field of diabetes. More particularly, the invention relates to a monomeric insulin analog wherein the A chain is the naturally occurring sequence of the human insulin A chain and the B chain is modified at either position B28 and B29 or both. The analog is mono-acylated at the N-terminal of the A chain or B chain or at the lysine. The acylated insulin analogs have an extended duration of action.

    摘要翻译: 本发明涉及糖尿病领域。 更具体地,本发明涉及单体胰岛素类似物,其中A链是人胰岛素A链的天然存在的序列,并且B链在位置B28和B29或两者都被修饰。 该类似物在A链或B链的N末端或赖氨酸单酰化。 酰化胰岛素类似物具有延长的作用持续时间。

    Acylated insulin analogs
    5.
    发明授权
    Acylated insulin analogs 失效
    酰化胰岛素类似物

    公开(公告)号:US5693609A

    公开(公告)日:1997-12-02

    申请号:US342931

    申请日:1994-11-17

    CPC分类号: C07K14/62 A61K38/00

    摘要: The present invention relates to the field of diabetes. More particularly, the invention relates to a monomeric insulin analog wherein the A chain is the naturally occurring sequence of the human insulin A chain and the B chain is modified at either position B28 and B29 or both. The analog is mono-acylated at the N-terminal of the A chain or B chain or at the lysine. The acylated insulin analogs have an extended duration of action.

    摘要翻译: 本发明涉及糖尿病领域。 更具体地,本发明涉及单体胰岛素类似物,其中A链是人胰岛素A链的天然存在的序列,并且B链在位置B28和B29或两者都被修饰。 该类似物在A链或B链的N末端或赖氨酸单酰化。 酰化胰岛素类似物具有延长的作用持续时间。